The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/ eukaryotic translation initiation factor 4E (eIF-4E)/ RAF pathway and activation is a mechanism of resistance

Journal of Biological Chemistry

Volumn 287, Issue 26, 2012, Pages 21796-21805

  Hoang, Bao ^a   Benavides, Angelica ^a   Shi, Yijiang ^a   Yang, Yonghui ^a   Frost, Patrick ^a   Gera, Joseph ^a   Lichtenstein, Alan ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; AKT ACTIVATION; CELL LINES; COMPLEX 1; ECTOPIC EXPRESSIONS; EQUIMOLAR CONCENTRATIONS; ERK ACTIVATION; EUKARYOTIC TRANSLATION; EXTRACELLULAR SIGNAL-REGULATED KINASE; INITIATION FACTORS; KINASE ACTIVITY; LETHAL EFFECTS; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); MULTIPLE MYELOMA; PI3-KINASE; PRIMARY CELLS; RAPAMYCIN; TARGET OF RAPAMYCIN; TUMOR MODELS;

ACTIVATION ANALYSIS; CELL CULTURE; DRUG THERAPY; ENZYME INHIBITION; PHOSPHORYLATION;

ANTIBIOTICS;

INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PP 242; RAF PROTEIN; RAPAMYCIN; S6 KINASE; SERINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

APOPTOSIS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-4E; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUTATHIONE TRANSFERASE; HUMANS; INDOLES; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PURINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84862703623     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.304626     Document Type: Article

References (31)

1. Alessi, D. R., Pearce, L. R., and Garcia-Martinez, J. M. (2009) Early events of B cell activation by antigen. Science Signaling 2, 1-4
2. Shi, Y., Yan, H., Frost, P., Gera, J., and Lichtenstein, A. (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4, 1533-1540
3. O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., Baselga, J., and Rosen, N. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508
4. Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., and Khuri, F. R. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058
5. Hoang, B., Frost, P., Shi, Y., Belanger, E., Benavides, A., Pezeshkpour, G., Cappia, S., Guglielmelli, T., Gera, J., and Lichtenstein, A. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-4568
6. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., Papa, A., Nardella, C., Cantley, L. C., Baselga, J., and Pandolfi, P. P. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074
7. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
8. Sharma, S., Nemeth, E., Chen, Y. H., Goodnough, J., Huston, A., Roodman, G. D., Ganz, T., and Lichtenstein, A. (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin. Cancer Res. 14, 3262-3267
9. Shi, Y., Gera, J., Hu, L., Hsu, J. H., Bookstein, R., Li, W., and Lichtenstein, A. (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62, 5027-5034
10. Shi, Y., Sharma, A., Wu, H., Lichtenstein, A., and Gera, J. (2005) Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J. Biol. Chem. 280, 10964-10973
11. Bondzi, C., Grant, S., and Krystal, G. W. (2000) A novel assay for the measurement of Raf-1 kinase activity. Oncogene. 19, 5030-5033
12. Reynolds, L. F., de Bettignies, C., Norton, T., Beeser, A., Chernoff, J., and Tybulewicz, V. L. (2004) Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J. Biol. Chem. 279, 18239-18246
13. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332, 83-85
14. McMillin, D. W., Ooi, M., Delmore, J., Negri, J., Hayden, P., Mitsiades, N., Jakubikova, J., Maira, S. M., Garcia-Echeverria, C., Schlossman, R., Munshi, N. C., Richardson, P. G., Anderson, K. C., and Mitsiades, C. S. (2009) Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 69, 5835-5842
15. Solit, D. B., Garraway L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., Golub, T. R., Sebolt-Leopold, J., Sellers, W. R., and Rosen, N. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362
16. Mody, N., Leitch, J., Armstrong, C., Dixon, J., and Cohen, P. (2001) Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 502, 21-24
17. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L. E., Bollag, G., and Trail, P. A. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109
18. Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., Drew, L., Haber, D. A., and Settleman, J. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861
19. Shelton, J. G., Moye, P. W., Steelman, L. S., Blalock, W. L., Lee, J. T., Franklin, R. A., McMahon, M., and McCubrey, J. A. (2003) Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17, 1765-1782
20. Chong, H., Vikis, H. G., and Guan, K. L. (2003) Mechanisms of regulating the Raf kinase family. Cellular Signalling 15, 463-469
21. Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland T. D., Conrads T. P., Veenstra, T. D., Lu, K. P., Morrison, D. K. (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224
22. Heidorn, S. J., Milagre C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., and Marais, R. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221
23. Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., and Gray, N. S. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032
24. Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., and Shokat, K. M. (2009) Active site inhibitors of mTOR target rapamycin-resistant outputs of TORC1 and TORC2. PLoS Biol. 7, 371-382
25. Hoang, B., Benavides, A., Shi, Y., Frost, P., and Lichtenstein, A. (2009) Effect of autophagy on multiple myeloma cell viability. Mol. Cancer Ther. 8, 1974-1984
26. Hay, N. (2010) Mnk earmarks eIF4E for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 107, 13975-13976
27. Wendel, H. G., Silva, R. L., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., and Lowe, S. W. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232-3237
28. Annunziata, C. M., Hernandez, L., Davis, R. E., Zingone, A., Lamy, L., Lam, L. T., Hurt, E. M., Shaffer, A. L., Kuehl, W. M., and Staudt, L. M. (2011) A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117, 2396-2404
29. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331
30. Scheid, M. P., Schubert, K. M., and Duronio, V. (1999) Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J. Biol. Chem. 274, 31108-31113
31. Chang, F., Steelman, L. S., Shelton, J. G., Lee, J. T., Navolanic, P. M., Blalock, W. L., Franklin, R., and McCubrey, J. A. (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int. J. Oncol. 22, 469-480